Alopexx, Inc. (ALPX)
Alopexx will go public soon, but the exact IPO date is still unknown.
IPO Price
$5.00
Shares Offered
2,400,000
Deal Size
$12.00M

Company Description

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).

To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections.

In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed.

It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine’s broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases.

Similarly, our fully human monoclonal antibody, F598, that also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials.

We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU).

Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation.

Alopexx, Inc.
CountryUnited States
Founded2006
IndustryHealth Care
SectorBiotechnology
CEODaniel R. Vlock

Contact Details

Address:
186 Alewife Brook Pkwy #1068
Cambridge, MA 02138
United States
Phone(617) 780-1598
Websitealopexx.com

Stock Details

Ticker SymbolALPX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$5.00
CIK Code0001880995
Employer ID86-3959763
SIC Code2836

Key Executives

NamePosition
Daniel R Vlock, MDPresident, Chief Executive Officer and Director
Thomas T. ThomasChief Financial Officer
Gerald B. Pier, PhDChief Scientific Officer
William W. Chin, MDSenior Strategic Advisor, Director
Christine de los Reyes, PharmD, MBAChief Business Officer, Chief Commercialization Officer
Peter J. WerthDirector

Latest SEC Filings

DateTypeTitle
Feb 25, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jan 8, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Sep 9, 2024S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Mar 14, 2024S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Dec 27, 2023S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Feb 1, 2023FWPFree Writing Prospectus
Feb 1, 2023S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Dec 15, 2022S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Nov 18, 2022S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Oct 7, 2022S-1/A[Amend] General form for registration of securities under the Securities Act of 1933